Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

CING

CING News

Newswire

11:39

Cingulate Reinstates Shane Schaffer as CEO, Focused on ADHD Treatment

05:31

Ascendiant Capital Downgrades Cingulate to Buy, PT to $58.

07:42

Cingulate Price Target Lowered to $16 at Roth Capital

13:02

Cingulate: Roth Capital maintains Buy rating, lowers PT to $16 from $17.

08:10

Cingulate Reports Q3 Results, FDA Accepts NDA for CTx-1301, May 2026 PDUFA Date.

View More

About CING

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More